Key result
Liraglutide improved the myocardial salvage index at 3 months compared to placebo in patients with STEMI undergoing primary PCI (0.66 vs 0.55; P=0.001).
Why the study?
Does subcutaneous liraglutide improve myocardial salvage index in patients with ST-segment-elevation myocardial infarction undergoing emergency primary percutaneous coronary intervention?
Population
96 patients with acute ST-segment-elevation myocardial infarction undergoing emergency primary percutaneous…
Comparison
Subcutaneous liraglutide commenced 30 minutes… vs Placebo
Design
RCT, randomized
Follow-up
6 months
Authors
Loading...
Liraglutide reduced no-reflow after primary PCI in STEMI; extends preclinical reperfusion protection to humans and warrants larger outcome trials.
RCT (n=96)
randomized
Does subcutaneous liraglutide improve myocardial salvage index in patients with ST-segment-elevation myocardial infarction undergoing emergency primary percutaneous coronary intervention?
Absolute Event Rate: 0.66% vs 0.55%
p-value: p=0.001
Peri-procedural administration of liraglutide significantly improved myocardial salvage index and reduced final infarct size in patients with STEMI undergoing primary PCI.
Chen et al. (2016) conducted an RCT in ST-segment-elevation myocardial infarction (n=96). Liraglutide vs. Placebo was evaluated on salvage index at 3 months (p=0.001). Liraglutide improved the myocardial salvage index at 3 months compared to placebo in patients with STEMI undergoing primary PCI (0.66 vs 0.55; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: